Florida is currently home to 3760 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Miami, Tampa, Jacksonville and Orlando. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
Recruiting
The main goal of this trial is to learn whether eptinezumab helps reduce the number of days with episodic migraine in pediatric participants.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
04/10/2025
Locations: Child Neurology of NW Florida, Gulf Breeze, Florida
Conditions: Episodic Migraine
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
Recruiting
The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmonary disease (COPD) who have completed the 52-week placebo-controlled treatment period in parent studies GB43311 or GB44332.
Gender:
ALL
Ages:
Between 40 years and 90 years
Trial Updated:
04/10/2025
Locations: St Francis Medical Institute ClinEdge PPDS, Clearwater, Florida
Conditions: Chronic Obstructive Pulmonary Disease
A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma
Recruiting
This trial is a phase 1b/2, open-label, multicenter study of GC012F (AZD0120), a CD19/BCMA dual CART-cell therapy, in adult subjects with relapsed/refractory Multiple Myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: Research Site, Jacksonville, Florida
Conditions: Relapsed/ Refractory Multiple Myeloma
Together After Cancer
Recruiting
To evaluate the impact of an adapted online, self-help relationship intervention (supplemented with brief coach calls) for survivors of breast cancer and their partners. Couples will be randomized to receive either the online intervention (Together after Cancer) or usual care (UC) and assessed at baseline, end of the program, and 3 months after randomization.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/10/2025
Locations: Sylvester Comprehensive Cancer Center and University of Miami, Miami, Florida
Conditions: Breast Cancer, Quality of Life, Communication
Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia
Recruiting
This is a hybrid (retrospective and prospective) non-interventional registry study to further describe the clinical profile of zanubrutinib in Waldenström macroglobulinemia (WM) participants with and without specific mutations and from racial and ethnic minority groups. Data collected from this registry study will be used to better understand the clinical benefit and safety of zanubrutinib for the treatment of participants in these populations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: Brcr Medical Center, Inc, Plantation, Florida
Conditions: Waldenstrom Macroglobulinemia
24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDG
Recruiting
This is a Phase 2, randomized, open-label, 24-week treatment study to evaluate the potential pharmacodynamic (PD) activity, safety, tolerability, and pharmacokinetics (PK) of GLM101 in adult, adolescent, and pediatric, patients with a confirmed diagnosis of PMM2-CDG. The planned doses of GLM101 to be investigated are 10, 20, and 30 mg/kg. The study will consist of a Screening Period, a 24-week (6-month) Treatment Period, and a 30-day (1-month) Follow-Up Period.
Gender:
ALL
Ages:
Between 2 years and 65 years
Trial Updated:
04/10/2025
Locations: Clinical Research of West Florida, Tampa, Florida
Conditions: Pmm2-CDG, Phosphomannomutase 2 Deficiency
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
Recruiting
This registry evaluates patient characteristics, real-world treatment patterns, and short- and long-term outcomes in a population of patients in the United States and Europe with symptomatic obstructive hypertrophic cardiomyopathy (HCM) who are receiving mavacamten, receiving other treatment for obstructive HCM, or not receiving treatment for obstructive HCM due to intolerance or failure of prior treatment. United States Sub-Study: The purpose of this study is to evaluate the safety of mavacamt... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: Uf Health Jacksonville, Jacksonville, Florida
Conditions: Obstructive Hypertrophic Cardiomyopathy
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
Recruiting
This is the first clinical trial of IDRX-42. The study is designed to evaluate the safety, tolerability, PK, and preliminary antitumor activity of IDRX-42 in adult participants with advanced (metastatic and/or surgically unresectable) GIST.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: University of Miami, Miami, Florida
Conditions: Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases, Metastatic Cancer
A Study to Learn About The COVID-19 (Study) Vaccine (Called COMIRNATY) in People That Are Less Than 21 Years Old.
Recruiting
The purpose of this clinical trial is to learn about the safety and effects of the study vaccine (called COMIRNATY) for the potential prevention of COVID-19. This study is seeking participants who: 1. Are age \<21 years. 2. Have presentation to participating medical center with evaluation in Emergency Room and/or hospitalization. 3. Received either the 1st, 2nd, 3rd or booster dose(s) of COMIRNATY within 7 days of symptom onset. 4. Meet criteria of Centers for Disease Control and Prevention cas... Read More
Gender:
ALL
Ages:
Between 0 years and 20 years
Trial Updated:
04/10/2025
Locations: Memorial Healthcare System, Hollywood, Florida
Conditions: Myocarditis
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
Recruiting
The main goal of the study is to assess the long-term safety of eptinezumab on children and adolescents ages 6 to 17 with chronic or episodic migraine.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
04/10/2025
Locations: NW FL Clinical Research Group, LLC, Gulf Breeze, Florida
Conditions: Migraine
Study of Screening Brain MRIs in Stage IV Breast Cancer
Recruiting
The study is a single arm, nonrandomized phase II prospective study, with the goal of investigating the role of screening brain MRIs in neurologically asymptomatic patients with metastatic breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: Morton Plant Mease- Baycare, Clearwater, Florida
Conditions: Triple Negative Breast Cancer, HER2-positive Breast Cancer, Hormone Receptor-positive Breast Cancer
An Observational Study of Carbaglu® for the Treatment of MMA and PA in Adults and Pediatrics
Recruiting
To obtain short-term and long-term clinical safety information, in pediatric and adult patients with PA and MMA treated with Carbaglu®.
Gender:
ALL
Ages:
All
Trial Updated:
04/10/2025
Locations: University of South Florida, Tampa, Florida
Conditions: Hyperammonemia, Methylmalonic Acidemia, Propionic Acidemia